Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Abstract The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …
GLP− 1 receptor agonists for the treatment of obesity: Role as a promising approach
JY Wang, QW Wang, XY Yang, W Yang… - Frontiers in …, 2023 - frontiersin.org
Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …
by genetic, environmental and other factors. In recent years, there has been an increase in …
From animal poisons and venoms to medicines: achievements, challenges and perspectives in drug discovery
Animal poisons and venoms are comprised of different classes of molecules displaying wide-
ranging pharmacological activities. This review aims to provide an in-depth view of toxin …
ranging pharmacological activities. This review aims to provide an in-depth view of toxin …
Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …
growing global concern. These comorbidities include type 2 diabetes, hypertension …
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …
care systems. Improving metabolic control to approach normal glycaemia (where practical) …
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
JJ Meier - Nature Reviews Endocrinology, 2012 - nature.com
In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Currently, six glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are approved for
treating type 2 diabetes. These fall into two classes based on their receptor activation: short …
treating type 2 diabetes. These fall into two classes based on their receptor activation: short …
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Alzheimer's disease (AD) and Parkinson's disease (PD) are the most frequent
neurodegenerative disorders. Despite their pathophysiological and clinical differences, they …
neurodegenerative disorders. Despite their pathophysiological and clinical differences, they …
Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications
Glucagon-like peptide-1 (GLP-1) is an incretin that plays important physiological roles in
glucose homeostasis. Produced from intestine upon food intake, it stimulates insulin …
glucose homeostasis. Produced from intestine upon food intake, it stimulates insulin …
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease
PL McClean, C Hölscher - Neuropharmacology, 2014 - Elsevier
Type 2 diabetes is a risk factor for develo** Alzheimer's disease (AD). In the brains of AD
patients, insulin signalling is desensitised. The incretin hormone Glucagon-like peptide-1 …
patients, insulin signalling is desensitised. The incretin hormone Glucagon-like peptide-1 …